source
- BioNTech's head and neck cancer mRNA vaccine fails to extend progression-free survival in Phase 3 trialBioNTech reported that its experimental mRNA immunotherapy BNT113 did not meet its primary endpoint in a Phase 3 trial for a specific head and neck cancer, failing to improve progression-free survi…
- Par Health initiates voluntary recall of Argatroban injection after detecting particulate contaminantsPar Health USA announced a voluntary nationwide recall of its Argatroban Injection 250 mg/2.5 mL product, affecting 22 lots that have been distributed to hospitals and users. The recall was trigge…fda recalls · 1mo agoRegulatoryNegative